CEO Executive AssistantBooking a virtual EA consultation for pharmaceutical and biotech CEOs is typically the first step in the hiring process with any managed service. The consultation is your opportunity to evaluate the service, communicate your pharmaceutical-specific requirements, and determine whether the provider’s matching capabilities meet your needs.
Most pharmaceutical executives who book these consultations without preparation get a generic sales pitch. Those who prepare specific, targeted questions get genuinely useful information. This guide helps you get the latter.
Why Consultations Matter More for Pharma CEOs
For most industries, a virtual EA consultation is fairly straightforward: describe what you need, hear about the service, ask about pricing, and decide whether to proceed. For pharmaceutical and biotech CEOs, the consultation is a more significant evaluation exercise.
Your needs are industry-specific in ways that matter operationally. A service that claims to support pharmaceutical executives needs to demonstrate actual knowledge of what pharmaceutical executive support involves: regulatory calendars, investor relations programs, clinical data confidentiality, and communication standards that meet FDA and investor expectations.
The consultation is where you discover whether the service actually understands your industry or is simply claiming broad executive support capability.
What to Prepare Before Booking
The most effective consultations are those where you arrive with specific, detailed information about your requirements. Before booking, prepare the following.
A Scope Document: One to two pages describing your role, your key responsibilities, the administrative tasks that consume the most time, and the pharmaceutical-specific context your EA needs to operate effectively. This document gives the service something concrete to match against rather than responding to a vague brief.
Specific Questions: Write out five to ten specific questions before the consultation. Without a written list, consultations easily drift toward the service’s talking points rather than your actual evaluation criteria.
Reference Request Intent: Decide in advance whether you will ask for references from pharmaceutical or biotech clients. If yes, state that intention clearly during the consultation and ask the service to prepare to provide those references.
Approximate Budget: Know your target monthly budget range before the consultation. This lets you quickly assess whether the service is in your range without going through an extensive matching process only to find the pricing does not work.
Questions to Ask in Your Consultation
Use these questions to evaluate any managed EA service from a pharmaceutical CEO perspective.
On Pharmaceutical Experience
“Do you currently serve pharmaceutical or biotech CEO clients? Can you describe what their EA support typically involves?”
“What percentage of your EA talent pool has direct experience supporting executives in regulated industries?”
“How do you prepare your EAs for the specific context requirements of pharmaceutical clients?”
On Matching Quality
“Describe your matching process. How do you determine which EA is the right fit for my specific role and operational needs?”
“What information do you gather from me to make the matching decision?”
“What is your typical timeline from consultation to EA start date?”
On Confidentiality and Security
“What NDA terms govern the EA relationship? Are those terms appropriate for pharmaceutical-specific confidentiality requirements?”
“What background checks do you conduct on EAs before placing them with clients in regulated industries?”
“How do you handle data handling protocols for clients who work with clinical or pre-filing regulatory information?”
On Service Level and Reliability
“What response time commitments do you make in writing? What are the consequences if those commitments are not met?”
“What is your average replacement turnaround time when an EA becomes unavailable?”
“What account management support is available to me if I experience issues with my EA?”
For a comparison of services that perform well on these criteria for pharmaceutical executives, see EA services for pharma. For an overview of the best dedicated EA services for pharmaceutical CEOs, dedicated EA for pharma covers that model specifically.
How to Evaluate Consultation Quality
The quality of a service consultation tells you a great deal about how the service will perform after you sign.
Does the service ask good questions? Strong services ask detailed questions about your role, your operational needs, and your pharmaceutical-specific context. Services that primarily talk about themselves and ask few questions about your situation are not positioning themselves to make a good match.
Do they have specific pharmaceutical examples? When you ask whether they serve pharmaceutical clients, can they describe specific aspects of what those clients need? Or do they offer generic statements about executive support? Specific, knowledgeable answers are a positive signal.
Are they honest about limitations? Strong services are willing to acknowledge what they cannot do. If you ask whether their EAs have pharmaceutical backgrounds and the honest answer is “not specifically, but they learn quickly,” that transparency is preferable to an overclaim.
Is pricing transparent? Services that provide clear, specific pricing during the consultation are more trustworthy than those who keep pricing vague until later in the process.
After the Consultation: Making Your Decision
After completing consultations with two to three services, evaluate them against your criteria and make a decision within a week. Prolonged indecision does not improve the outcome, and the time you spend without EA support has a real cost.
The decision criteria for a pharmaceutical CEO:
- Does the service have demonstrated pharmaceutical or life sciences client experience?
- Does the matching process account specifically for my pharmaceutical requirements?
- Is the pricing within my target range?
- Are the confidentiality and NDA terms adequate for my operational needs?
- Is there a replacement guarantee with a specific, written turnaround commitment?
- Did the service representative demonstrate genuine knowledge of pharmaceutical executive support requirements, or did they give only generic answers?
Research from McKinsey confirms that the executives who invest deliberately in sourcing high-quality administrative support achieve significantly better outcomes than those who default to the most convenient option. The consultation process is where that deliberate investment starts.
Conclusion
Booking a virtual EA consultation for pharmaceutical and biotech CEOs is the first step in a process that should be specific, deliberate, and pharmaceutical-aware. Prepare a scope document, write your questions in advance, and evaluate consultation quality as an indicator of service quality. The pharmaceutical executives who ask the hardest questions in consultations make the best service selections, because they surface what the service actually knows about their industry context before signing a contract.
Related Reading
For further context, explore Book a Virtual EA Consultation for Automotive CEOs and Book a Virtual EA Consultation for Construction & Architecture CEOs.